Adenocarcinoma of the Lung
Find comprehensive information on Adenocarcinoma of the Lung, also known as Lung Adenocarcinoma and Pulmonary Adenocarcinoma. This resource offers guidance on healthcare, clinical documentation, and medical coding related to this lung cancer diagnosis. Learn about symptoms, staging, treatment options, and best practices for accurate medical coding and documentation of Adenocarcinoma of the Lung.
A type of non-small cell lung cancer originating in mucus-producing gland cells.
Persistent cough, shortness of breath, chest pain, hemoptysis, fatigue, weight loss.
Detected on chest X-ray, CT scan, or biopsy. Often diagnosed in advanced stages.
ICD-10 Code Families
Complete code families applicable to C34.90
When to use each related code
| Description | When to use |
|---|---|
| Most common type of lung cancer. Starts in mucus-producing glands. | Use for malignant tumors originating in glandular cells of the lung. Specify histology if known. |
| Type of NSCLC arising from squamous cells lining the airways. | Use for malignant tumors originating in squamous epithelium of the lung. Often centrally located. |
| Aggressive form of lung cancer, often with neuroendocrine features. | Use for rapidly growing lung tumors, often with poor prognosis. Consider immunohistochemistry. |
Best-practice checklist
- ✓Document TNM stage (size, nodes, mets)
- ✓Confirm histology with pathology report
- ✓Specify primary or secondary lung cancer
- ✓Record location and laterality (e.g., RUL)
- ✓Note symptoms and performance status
Common pitfalls to avoid
Unspecified histology (e.g., NOS) may lead to downcoding or claim denials. Ensure proper documentation of cell type for accurate coding (e.g., ICD-10 C34.x).
Missing laterality (right/left lung) impacts coding and reimbursement. Clear documentation is crucial for accurate ICD-10 coding (e.g., C34.11, C34.21).
Incomplete staging data (TNM) affects severity and treatment. Thorough documentation is essential for proper ICD-10 and treatment coding.
Best-practice tips
- 01Accurate ICD-10 coding (C34.-) for lung adenocarcinoma ensures proper reimbursement.
- 02Detailed clinical documentation improves lung adenocarcinoma diagnosis coding accuracy.
- 03Timely follow-up & treatment optimize lung adenocarcinoma patient outcomes & compliance.
- 04Molecular testing guides targeted therapy for specific lung adenocarcinoma mutations.
- 05Smoking cessation counseling is crucial for lung adenocarcinoma prevention & management.
Step-by-step checklist
- 1
Confirm lung adenocarcinoma diagnosis via histopathology report (ICD-10 C34)
- 2
Document tumor size, location, and laterality for accurate TNM staging and coding
- 3
Evaluate EGFR, ALK, PD-L1 biomarkers for targeted therapy consideration and coding
- 4
Assess patient for symptoms like cough, dyspnea, hemoptysis for clinical documentation
- 5
Review imaging (CT/PET) for metastasis to ensure accurate staging and treatment planning
Ready-to-paste narrative
Patient presents with complaints consistent with possible lung adenocarcinoma. Symptoms include persistent cough, hemoptysis, dyspnea, and unexplained weight loss. The patient reports a history of smoking (40 pack-years). Physical examination reveals decreased breath sounds and dullness to percussion in the right upper lobe. Imaging studies, including a chest X-ray and CT scan of the chest, demonstrate a suspicious pulmonary nodule. A subsequent bronchoscopy with biopsy was performed, and the pathology report confirmed the diagnosis of adenocarcinoma of the lung. Staging workup, including PET scan and mediastinoscopy, is underway to determine the extent of disease and guide treatment planning. Differential diagnoses considered included pneumonia, bronchitis, and other pulmonary malignancies. The patient's current performance status is ECOG 1. The case was discussed at the multidisciplinary thoracic oncology tumor board, and a treatment plan involving chemotherapy and potential surgical resection is being considered. The patient has been informed of the diagnosis, prognosis, and treatment options. Molecular testing for EGFR, ALK, and ROS1 mutations has been ordered to assess eligibility for targeted therapy. Follow-up appointments are scheduled for symptom management, treatment discussion, and continued surveillance. ICD-10 code C34.91 (malignant neoplasm of unspecified part of right upper lobe bronchus or lung) is recorded. This diagnosis impacts medical billing and coding by necessitating specific CPT codes for procedures performed and subsequent treatment. The patient's condition and treatment plan will be continuously monitored and documented in the electronic health record.
Common questions and answers
What are the most effective current treatment strategies for Stage IV EGFR-mutated Lung Adenocarcinoma with brain metastases?+
Treatment for Stage IV EGFR-mutated Lung Adenocarcinoma with brain metastases typically involves a combination of targeted therapy and radiation. First-line treatment often includes EGFR tyrosine kinase inhibitors (TKIs) like osimertinib, which have demonstrated efficacy in penetrating the blood-brain barrier and targeting both systemic and intracranial disease. For patients with symptomatic brain metastases or a high intracranial disease burden, stereotactic radiosurgery (SRS) or whole-brain radiotherapy (WBRT) may be considered in conjunction with or following TKI therapy. The choice between SRS and WBRT depends on factors such as the number and size of metastases, patient performance status, and the presence of neurologic symptoms. Regular monitoring with brain imaging (MRI) is essential to assess treatment response and manage intracranial disease progression. Explore how molecular profiling and liquid biopsies can personalize treatment strategies for patients with advanced lung adenocarcinoma. Consider implementing a multidisciplinary approach involving oncologists, radiation oncologists, pulmonologists, and neurosurgeons to optimize patient care and outcomes.
How can I differentiate between Lung Adenocarcinoma and Squamous Cell Carcinoma of the lung based on clinical presentation and diagnostic workup?+
While both Lung Adenocarcinoma and Squamous Cell Carcinoma are common subtypes of non-small cell lung cancer (NSCLC), they often exhibit distinct clinical and pathological features. Adenocarcinoma tends to occur more peripherally in the lungs and is more common in never-smokers or former light smokers. Patients with adenocarcinoma may present with symptoms like cough, shortness of breath, and chest pain. Squamous cell carcinoma is more centrally located and typically arises in current or former heavy smokers, often presenting with hemoptysis or post-obstructive pneumonia. Diagnosis relies heavily on imaging (CT scan, PET scan) and tissue biopsy. Histologically, adenocarcinoma is characterized by glandular formations and the production of mucin, while squamous cell carcinoma shows keratinization and intercellular bridges. Immunohistochemical staining can further differentiate these subtypes, with adenocarcinoma often positive for TTF-1 and Napsin A, while squamous cell carcinoma may express p63 and CK5/6. Accurate differentiation is crucial for determining optimal treatment strategies, as targeted therapies are more effective in specific NSCLC subtypes. Learn more about the role of bronchoscopy and endobronchial ultrasound (EBUS) in obtaining diagnostic tissue samples.
What are the latest advancements in immunotherapy for patients with advanced non-squamous non-small cell lung cancer (NSCLC), specifically adenocarcinoma, who have progressed on chemotherapy and targeted therapies?+
Immunotherapy, particularly immune checkpoint inhibitors, has revolutionized the treatment landscape for advanced non-squamous NSCLC, including adenocarcinoma. For patients who have progressed on chemotherapy and targeted therapies, immune checkpoint inhibitors like pembrolizumab, nivolumab, and atezolizumab can offer significant clinical benefit. These agents work by blocking immune checkpoints such as PD-1 or PD-L1, which allows the patient's immune system to recognize and attack cancer cells more effectively. PD-L1 expression testing is often performed to identify patients who are more likely to respond to these therapies. Furthermore, combination therapies involving checkpoint inhibitors and chemotherapy or anti-angiogenic agents are also being investigated and implemented for improved efficacy. Ongoing research is focusing on identifying novel biomarkers and developing next-generation immunotherapies to overcome resistance mechanisms and further improve outcomes for patients with advanced lung adenocarcinoma. Consider implementing a comprehensive biomarker testing strategy to personalize immunotherapy approaches and identify potential clinical trial opportunities for eligible patients.
Clinical accuracy: This information is provided for documentation and coding guidance and should not replace professional medical judgment.
Coding standard: ICD-10-CM, current FY guidelines.